公开(公告)号：US20230233543A1

公开(公告)日：2023-07-27

申请号：US17923420

申请日：2021-05-06

Applicant: Dompe' Farmaceutici SPA ,  FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. ,  KATHOLIEKE UNIVERSITEIT LEUVEN - KU LEUVEN R&D

Inventor： Andrea Rosario BECCARI ,  Candida MANELFI ,  Carmine TALARICO ,  Andrea ZALIANI ,  Gerd GEISSLINGER ,  Philip GRIBBON ,  Pieter LEYSSEN

IPC: A61K31/4535 ,  A61K31/473 ,  A61P31/14

CPC classification number: A61K31/4535 ,  A61K31/473 ,  A61P31/14

Abstract: The present invention relates to compounds that are able to inhibt functional proteins of COVID-19 virus, SARS-Cov-2.

公开(公告)号：US20240180889A1

公开(公告)日：2024-06-06

申请号：US18284951

申请日：2022-03-31

Applicant: Dompe' farmaceutici SpA

Inventor： Marcello ALLEGRETTI ,  Andrea Rosario BECCARI ,  Maria Candida CESTA ,  Elisabetta Maria Ester MAURI ,  Carmine TALARICO

IPC: A61K31/4535 ,  A61K39/00 ,  A61K39/215

CPC classification number: A61K31/4535 ,  A61K39/215 ,  A61K2039/53

Abstract: The present invention relates to the combination of a Selective Estrogen Receptor Modulator (SERM) and a COVID-19 vaccine.

公开(公告)号：US20240180888A1

公开(公告)日：2024-06-06

申请号：US18282357

申请日：2022-03-17

Applicant: Dompe' Farmaceutici SPA

Inventor： Marcello ALLEGRETTI ,  Andrea ARAMINI ,  Piergiorgio AMENDOLA ,  Laura BRANDOLINI ,  Maria Candida CESTA ,  Anna SIRICO

IPC: A61K31/451 ,  A61K31/427 ,  A61K39/00 ,  A61P37/08 ,  C07K16/28

CPC classification number: A61K31/451 ,  A61K31/427 ,  A61P37/08 ,  C07K16/2896 ,  A61K2039/505 ,  C07K2317/76

Abstract: The present invention relates to the use of a C5aR1 inhibitor for the prevention or treatment of a hypersensitivity reaction (HSR) to a taxane in an individual.

公开(公告)号：US20230357121A1

公开(公告)日：2023-11-09

申请号：US17922999

申请日：2021-05-04

Applicant: DOMPE' FARMACEUTICI SPA

Inventor： Andrea ARAMINI ,  Marcello ALLEGRETTI ,  Gianluca BIANCHINI ,  Samuele LILLINI ,  Mara TOMASSETTI

IPC: C07C59/84 ,  C07C229/26 ,  C07C229/28

CPC classification number: C07C59/84 ,  C07C229/26 ,  C07C229/28 ,  C07C2601/14 ,  C07B2200/13

Abstract: The present invention relates to a new co-crystal of Ketoprofen, Lysine and Gabapentin, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.

公开(公告)号：US20240156757A1

公开(公告)日：2024-05-16

申请号：US18279708

申请日：2022-03-03

Applicant: DOMPE' FARMACEUTICI SPA

Inventor： Marcello ALLEGRETTI ,  Laura BRANDOLINI ,  Annamaria VEZZANI ,  Rossella DI SAPIA ,  Teresa RAVIZZA ,  Silvia Maria BALOSSO

IPC: A61K31/18 ,  A61P25/08

CPC classification number: A61K31/18 ,  A61P25/08

Abstract: The present invention relates to a CXCL8 inhibitor and a pharmaceutical composition thereof, for use in the prevention or treatment of seizures.

公开(公告)号：US20240091311A1

公开(公告)日：2024-03-21

申请号：US18275849

申请日：2022-02-04

Applicant: DOMPE' FARMACEUTICI SPA

Inventor： Andrea ARAMINI ,  Pier Giorgio AMENDOLA ,  Anna SIRICO ,  Gaetano D'ANNIBALLE ,  Franca CATTANI ,  Marcello ALLEGRETTI ,  Flavio MANTELLI

IPC: A61K38/18 ,  A61P27/02

CPC classification number: A61K38/185 ,  A61P27/02

Abstract: The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.

公开(公告)号：US20230141355A1

公开(公告)日：2023-05-11

申请号：US17914529

申请日：2021-03-24

Applicant: Dompe' Farmaceutici SPA

Inventor： Marcello ALLEGRETTI ,  Flavio MANTELLI ,  Lorenzo PIEMONTI

IPC: A61K31/18 ,  A61K31/675 ,  A61K31/737 ,  A61K31/573 ,  A61K31/496 ,  A61K31/431 ,  A61K38/20 ,  A61K31/635 ,  A61K31/167 ,  A61K31/616 ,  A61K31/415 ,  A61K31/7052 ,  A61K31/546 ,  A61K31/135 ,  A61P31/14

CPC classification number: A61K31/18 ,  A61K31/675 ,  A61K31/737 ,  A61K31/573 ,  A61K31/496 ,  A61K31/431 ,  A61K38/2006 ,  A61K31/635 ,  A61K31/167 ,  A61K31/616 ,  A61K31/415 ,  A61K31/7052 ,  A61K31/546 ,  A61K31/135 ,  A61P31/14

Abstract: The present invention relates to CXCL8 inhibitors for use in the treatment of COVID-19 patients with pneumonia.

公开(公告)号：US20250025435A1

公开(公告)日：2025-01-23

申请号：US18702196

申请日：2022-10-25

Applicant: DOMPE' FARMACEUTICI SPA

Inventor： Andrea ARAMINI ,  Gianluca BIANCHINI ,  Samuele LILLINI ,  Mara TOMASSETTI ,  Laura BRANDOLINI

IPC: A61K31/192 ,  A61K9/14 ,  A61K31/195 ,  A61K31/198 ,  A61P29/00

Abstract: The present invention relates to new co-crystals of non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the class of phenylpropionic or phenylacetic acid derivatives. Lysine and Gabapentin, to their pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.

公开(公告)号：US20240424060A1

公开(公告)日：2024-12-26

申请号：US18763519

申请日：2024-07-03

Applicant: DOMPE' FARMACEUTICI SPA

Inventor： Andrea ARAMINI ,  Pier Giorgio AMENDOLA ,  Anna SIRICO ,  Gaetano D'ANNIBALLE ,  Franca CATTANI ,  Marcello ALLEGRETTI ,  Flavio MANTELLI

IPC: A61K38/18 ,  A61P27/02

Abstract: The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.

公开(公告)号：US20230390156A1

公开(公告)日：2023-12-07

申请号：US18034252

申请日：2021-10-27

Applicant: Dompe' Farmaceutici SpA

Inventor： Marcello ALLEGRETTI ,  Lucia APPARENTE ,  Marco Maria GENTILE ,  Simone MATTIOLI

IPC: A61J1/14 ,  A61K38/18

CPC classification number: A61J1/1468 ,  A61K38/185

Abstract: The present invention relates to a pharmaceutical package comprising a plastic container and an aqueous formulations of nerve growth factor (NGF), in which at least the surface of the container in contact with the NGF aqueous formulation is made of particular polypropylenes (PPs), characterized by certain thermal properties and crystallinity. Advantageously said containers show a NGF adhesion significantly lower than that of siliconized glass or of other polypropylenes. It is thus possible to store aqueous formulations of NGF in less severe conditions, avoiding additional coating treatments to the containers and additives while keeping the NGF titer constant.